PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

InflaRx closes USD55m Series D financing

InflaRx, a biopharmaceutical company developing new therapeutics in the terminal complement space, has closed a USD55 million Series D financing and investment round.

The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC, and complemented by certain investment funds managed by a leading US investment management firm. The transaction is comprised of a USD30 million capital increase and a USD25 million secondary share purchase. Proceeds from the capital increase will be used to advance clinical phase IIb development of InflaRx’s lead drug candidate IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in chronic inflammatory and auto-immune indications and to advance preclinical development of follow-up pipeline molecules.
 
In July 2017, InflaRx successfully completed a clinical Phase IIa open label trial in patients suffering from Hidradenitis Suppurativa, a chronic debilitating auto-inflammatory skin disease, which demonstrated the disease modifying activity of lead drug candidate IFX-1. This data was presented at two European meetings in September, the 16th European Meeting on Complement in Human Disease, Copenhagen and the 26th Meeting of the European Academy of Dermatology and Venerology, Geneva.

Like this article? Sign up to our free newsletter

FEATURED

MOST RECENT

FURTHER READING